Citigroup Maintains Buy on Caris Life Sciences, Lowers Price Target to $28

Benzinga Newsdesk www.benzinga.com Negative 53.0%

Neg 53% Neu 0% Pos 0%

Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $35 to $28.